Drug Trial Radar · NCT01959841
Phase III Study of ASP2151 in Herpes Zoster Patients
Last checked: Nov 19, 2026Latest source record: Nov 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
751
Actual
Start
Aug 2013
Primary completion
Jul 2015
Study completion Jul 10, 2015
Sponsor
- Lead sponsor
- Maruho Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.
Conditions
- Herpes Zoster
Interventions
ASP2151Drug
200 mg once daily or 400 mg once daily
valaciclovirDrug
1000 mg three times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study TreatmentTime frame: 4days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Sapporo, Hokkaido, Japan
Site not named
Yokohama, Kanagawa, Japan
Site not named
Nakano-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.